Catálogo de publicaciones - libros

Palabras clave – provistas por la editorial

Zika virus; nucleoside analogues; antiviral agents; NS5; prodrugs; ProTides; neural stem cells; RNA-dependent RNA polymerase; cytomegalovirus; latent infection; TALEN; Surveyor nuclease mutation detection assay; ie-1 gene; quantitative real-time PCR; Epstein–Barr virus; herpes viruses; lytic gene expression; Burkitt lymphoma cells; clozapine; antipsychotic drug; antiviral drug; enteroviruses; coxsackievirus B4; persistent infection; fluoxetine; resistance; mutations; herpes B virus; macacine herpesvirus-1; genistein; flavonoids; acyclovir; ganciclovir; Plantago asiatica; Clerodendrum trichotomum; RSV; therapeutic effects; acteoside; human antimicrobial peptides; antiviral strategies; defensins; cathelicidins; hepcidins; transferrins; influenza A virus; brevilin A; antiviral; sesquiterpene lactone; replication; PRRSV; polyethylenimine; PEI; virion internalization; endocytosis; HIV; pediatrics; Ethiopia; pre-treatment drug resistance; combination antiretroviral therapy (cART); dried plasma spots; dried blood spots; sphingolipids; glycosphingolipids; viruses; lipid biosynthesis; flavivirus; Japanese encephalitis virus; furin inhibitor; precursor membrane protein; measles virus; central nervous system; tropism; treatments; porcine reproductive and respiratory syndrome virus; ginsenoside Rg1; antiviral activity; pro-inflammatory factor; NF-κB signaling pathway; acute/latent infection; congenital infection; antiviral agent; therapeutic strategies; nucleic acid-based therapeutic approach; HCMV vaccine; adoptive cell therapy; Rev response element; chemical footprinting; SHAPE; drug discovery; branched peptides; herpesvirus; immediate-early; IE1; IE2; ribozyme; RNA interference; CRISPR/Cas; small molecule; orthohantavirus; phenyl-benzotriazoles; C-FRA; Porcine circovirus type 2; epigallocatechin gallate; heparan sulfate; antiviral effect; virus attachment; microvirin; lectin; human immunodeficiency virus; hepatitis C virus; antiviral inhibitor; non-immunogenic; viral entry; protein drugs; LUMS1; oleanane-type derivatives; influenza A virus (IAV); virus entry inhibitors; hemagglutinin (HA); n/a